Daiichi Sankyo details ADC leadership, oncology growth strategy

Daiichi Sankyo is hosting its Science & Technology Day 2025 on December 16, 2025, for institutional investors, analysts, and media. The event will focus on the company's robust oncology pipeline and strategic advancements. Key highlights include the strong global performance of Enhertu, which has treated 194,000 patients globally, and Datopotamab deruxtecan (Dato-DXd), with 10.4 bn yen in global net sales in Q2 FY2025. The company projects 900 bn yen in oncology revenue by 2025 and aims to be a top 10 oncology company.

The company's innovative DXd ADC platform has received 13 Breakthrough Therapy designations in the U.S. since 2017, underscoring its potential in treating various cancers, including HER2-positive breast, lung, and gastric cancers. Enhertu is expected to launch in first-line HER2+ metastatic breast cancer, potentially benefiting 24,000 eligible patients. Dato-DXd has shown promising efficacy in triple-negative breast cancer (TNBC) with a statistically significant improvement in PFS and OS compared to ICC. Daiichi Sankyo is also expanding its portfolio with new modalities, including STING agonists and targeted protein degraders, and strengthening its manufacturing and R&D capabilities through strategic investments and smart labs in San Diego and Tokyo to accelerate innovation.